Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers

Clinical Pharmacokinetics

Volumn 45, Issue 3, 2006, Pages 317-324

  Dhawan, Sanju ^a   Singh, Bhupinder ^a   Garg, Santosh Kumar ^b   Hota, Debasish ^b   Dash, Radharaman Jiban ^b   Singla, Anil Kumar ^a   Sinha, Vivek Ranjan ^a  

^a PANJAB UNIVERSITY   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLIPIZIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; HUMAN; LATIN SQUARE DESIGN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE;

ADOLESCENT; ADULT; ALGORITHMS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; GLIPIZIDE; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 33644636643     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645030-00007     Document Type: Article

References (39)

1. World Health Organization. Diabetes: the cost of diabetes [online]. Available from URL: http://www.who.int/mediacentre/factsheets/fs236/en/ [Accessed 2006 Jan 20]
2. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 Sep; 329 (14): 977-86
3. Reichard P, Britz A, Cars I, et al. The Stockholm Diabetes Intervention Study (SDIS): 18 months' results. Acta Med Scand 1988; 224 (2): 115-22
4. Wake N, Hisashige A, Katayama T, et al. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study. Diabetes Res Clin Pract 2000; 48 (3): 201-10
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998 Sep; 352 (9131): 837-53
6. Boyle PJ, Kempers SF, O'Connor AM, et al. Brain glucose uptake and unawareness of hypoglycemia in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995 Dec; 333 (26): 1726-31
7. Lebovitz HE. Glipizide: second-generation sulfonylurea hypoglycemic agent. Pharmacotherapy 1985 Mar-Apr; 5 (2): 63-77
8. Brogden RN, Heel RC, Pakes GE, et al. Glipizide: a review of its pharmacological properties and therapeutic use. Drugs 1979 Nov; 18 (5): 329-53
9. Peterson CM, Sims RV, Jones RL, et al. Bioavailability of glipizide and its effect on blood glucose and insulin levels in patients with non-insulin-dependent diabetes. Diabetes Care 1982 Sep-Oct; 5 (5): 497-500
10. Feinglos MN, Lebovitz HE. Long term safety and efficacy of glipizide. Am J Med 1983 Nov; 75 Suppl. 5B: 60-6
11. Berelowitz M, Fischette C, Cefalu W, et al. Comparative efficacy of once daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM. Diabetes Care 1994 Dec; 17 (12): 1460-4
12. Riddle MC, McDaniel PA, Tive LA. Glipizide-GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM. Diabetes Care 1997 Jun; 20 (6): 992-4
13. Kradjan WA, Takeuchi KY, Opheim KE, et al. Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses. Pharmacotherapy 1995 Jul-Aug; 15 (4): 465-71
14. Blonde L, Guthrie RD, Tive L, et al. Glipizide GITS is effective and safe in a wide range of NIDDM patients: results of a double blind, placebo controlled efficacy and safety trial. The Glipizide GITS Efficacy and Safety Trial Study Group. Diabetes 1996; 45 Suppl. 2: 285A
15. Verma RK, Mishra B, Garg S. Osmotically controlled oral drug delivery. Drug Dev Ind Pharm 2000 Jul; 26 (7): 695-708
16. Miglani (Dhawan) S. Preparation and evaluation of controlled release oral dosage forms of glipizide and nifedipine [PhD thesis abstract]. Panjab University Research Journal (Science) 2003; 53: 213-4
17. Dhawan S, Singla AK, inventors. Composition and a method of maintaining blood glucose level. U.S. patent 6,703,045, 2004 Mar 9
18. Dhawan S, Singla AK, inventors. Composition and a method of maintaining blood glucose level by employing the hydrophilic matrix based oral controlled release antidiabetic composition. Indian patent 2001, 965/DEL, 2001 Aug 19
19. Indian Council of Medical Research. Ethical guidelines for biomedical research on human subjects. New Delhi: Indian Council of Medical Research, 2000
20. Good clinical practices: guidelines for clinical trials on pharmaceutical products in India. New Delhi: Central Drugs Standard Control Organisation, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, 2001
21. Guidance to industry: glipizide invivo bioequivalence and invitro dissolution testing. Rockville (MD): Center for Drug Evaluation and Research, Food and Drug Administration, Division of Bioequivalence, Office of Generic Drugs, 1999
22. Dhawan S, Singla AK. Performance liquid chromatographic analysis of glipizide: application to in vitro and in vivo studies. J Chromatographic Sci 2003 Jul; 41 (6): 295-300
23. Yeh KC, Kwan KC. A comparison of numerical algorithm by trapezoidal, lagrange and spline approximation. J Pharmacokinet Biopharm 1978; 6 (1): 79-98
24. Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 1978 Dec; 6 (6): 547-58
25. Riegelman S, Collier P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 1980 Oct; 8 (5): 509-34
26. Scientific Consulting Incorporation. PCNonlin 4.0 user's guide 8509 for PCNonlin-version 4.2. Apex (NC): Scientific Consulting Incorporation, 1992
27. Wagner J. Fundamentals of clinical pharmacokinetics. 1st ed. Hamilton (IL): Drug Intelligence Publications Inc., 1975: 301-2
28. Gennaro AF. Statistics. In: Gennaro AF, editor. Remington: the science and practice of pharmacy. Vol. I. 20th ed. New York: Lippincott William & Wilkins, 2002: 124-5
29. Fucella LM, Tamassia V, Valzelli G. Metabolism and kinetics of the hypoglycemia agent glipizide in man: comparison with glibenclamide. J Clin Pharmacol New Drugs 1973 Feb-Mar; 13 (2): 68-75
30. Balant L, Zahnd G, Gorgia A, et al. Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia 1973 Sep; 9 Suppl.: 331-8
31. Schmidt HA, Schoog M, Schweer KH, et al. Pharmacokinetics and pharmacodynamics as well as metabolism following orally and intravenously administered 14C glipizide, a new antidiabetic. Diabetologia 1973 Sep; 9 Suppl.: 320-30
32. Wahlin-Boll E, Almer LO, Melander A. Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetes. Clin Pharmacokinet 1982 Jul-Aug; 7 (4): 363-72
33. Huupponen R, Seppala P, Lisaio E. Glipizide pharmacokinetics and response to diabetics. Int J Clin Ther Toxicol 1982 Sep; 20 (9): 417-22
34. Wahlin-Boll E, Melander A, Sartor G, et al. Influence of food intake on the absorption and effect of glipizide in diabetics and differin healthy subjects. Eur J Clin Pharmacol 1980 Oct; 18 (3): 279-83
35. Chung M, Kaurides I, Canovatchel W, et al. Pharmacokinetics and pharmacodynamics of extended release glipizide GITS compared with immediate release glipizide in patients with type 2 diabetes mellitus. J Clin Pharmacol 2002 Jun; 42 (6): 651-7
36. Endrenyi L, Fritsch S, Yan W. Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence. Int J Clin Pharmacol Ther Toxicol 1991 Oct; 29 (10): 394-9
37. Schall R, Luus HG. Comparison of absorption rates in bioequivalence studies of immediate release drug formulations. Int J Clin Pharmacol Ther Toxicol 1992 May; 30 (5): 153-9
38. max/AUC in investigations of bioequivalence. Int J Clin Pharmacol Ther Toxicol 1993 April; 31 (4): 184-9
39. Lacey LF, Keene ON, Duquesnoy C, et al. Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies. J Pharm Sci 1994 Feb; 83 (2): 212-5